JP2025503546A5 - - Google Patents
Info
- Publication number
- JP2025503546A5 JP2025503546A5 JP2024539566A JP2024539566A JP2025503546A5 JP 2025503546 A5 JP2025503546 A5 JP 2025503546A5 JP 2024539566 A JP2024539566 A JP 2024539566A JP 2024539566 A JP2024539566 A JP 2024539566A JP 2025503546 A5 JP2025503546 A5 JP 2025503546A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- car
- optionally
- hla
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163295491P | 2021-12-30 | 2021-12-30 | |
| US63/295,491 | 2021-12-30 | ||
| PCT/US2022/082431 WO2023129929A1 (en) | 2021-12-30 | 2022-12-27 | Cd4+ t cells expressing il-10 and chimeric antigen receptors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025503546A JP2025503546A (ja) | 2025-02-04 |
| JP2025503546A5 true JP2025503546A5 (enExample) | 2026-01-07 |
Family
ID=85172951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024539566A Pending JP2025503546A (ja) | 2021-12-30 | 2022-12-27 | Ｉｌ－１０およびキメラ抗原受容体を発現するｃｄ４＋ｔ細胞およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20250108113A1 (enExample) |
| EP (1) | EP4456927A1 (enExample) |
| JP (1) | JP2025503546A (enExample) |
| KR (1) | KR20250005566A (enExample) |
| CN (1) | CN119136843A (enExample) |
| AR (2) | AR128124A1 (enExample) |
| AU (1) | AU2022423984A1 (enExample) |
| CA (1) | CA3244829A1 (enExample) |
| IL (1) | IL313935A (enExample) |
| TW (1) | TW202334400A (enExample) |
| WO (1) | WO2023129929A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025235772A1 (en) * | 2024-05-09 | 2025-11-13 | Cabaletta Bio, Inc. | Methods and compositions for preparing genetically modified immune cells |
| WO2026015450A1 (en) * | 2024-07-06 | 2026-01-15 | Tr1X, Inc. | Cd4+ t cells expressing il-10 and chimeric antigen receptors and uses thereof |
| EP4678187A1 (en) * | 2024-07-11 | 2026-01-14 | Medizinische Hochschule Hannover | Compound for use in the treatment of inflammatory bowel disease |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| MX341884B (es) | 2009-03-10 | 2016-09-07 | Biogen Ma Inc | Anticuerpos anti-antigeno de maduracion de celulas b (bcma). |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| KR20140004174A (ko) | 2011-01-18 | 2014-01-10 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암 치료를 위한 조성물 및 방법 |
| CN103946952A (zh) | 2011-09-16 | 2014-07-23 | 宾夕法尼亚大学董事会 | 用于治疗癌症的rna改造的t细胞 |
| RU2766608C2 (ru) | 2012-04-11 | 2022-03-15 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток |
| WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| JP6647868B2 (ja) | 2013-02-20 | 2020-02-14 | ノバルティス アーゲー | ヒト化抗ＥＧＦＲｖＩＩＩキメラ抗原受容体を用いたがんの処置 |
| US9790282B2 (en) | 2013-03-25 | 2017-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD276 polypeptides, proteins, and chimeric antigen receptors |
| AU2015244039B2 (en) | 2014-04-07 | 2021-10-21 | Novartis Ag | Treatment of cancer using anti-CD19 chimeric antigen receptor |
| JP7237449B2 (ja) | 2015-02-27 | 2023-03-13 | アイセル・ジーン・セラピューティクス・エルエルシー | 血液系腫瘍を標的としたキメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| DK3268013T3 (da) | 2015-03-13 | 2021-12-20 | Fond Telethon | Il-10-producerende cd4+-t-celler til anvendelse ved behandling af en cancer |
| WO2016197064A1 (en) * | 2015-06-04 | 2016-12-08 | Epstein Alan L | Lym-1 and lym-2 targeted car cell immunotherapy |
| GB201513540D0 (en) | 2015-07-31 | 2015-09-16 | King S College London | Therapeutic agents |
| US10562952B2 (en) | 2015-09-10 | 2020-02-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD276 chimeric antigen receptors |
| US11365391B2 (en) * | 2015-09-28 | 2022-06-21 | Trustees Of Dartmouth College | Chimeric antigen receptor anti-inflammatory cells and methods of use |
| KR20230148844A (ko) | 2016-03-29 | 2023-10-25 | 유니버시티 오브 써던 캘리포니아 | 암을 표적하는 키메라 항원 수용체 |
| ES2981703T3 (es) | 2016-09-02 | 2024-10-10 | Lentigen Tech Inc | Composiciones y métodos para tratar cáncer con DuoCars |
| DK3523326T3 (da) | 2016-10-04 | 2020-08-03 | Prec Biosciences Inc | Samstimulerende domæner til anvendelse i genetisk modificerede celler |
| CA3067914A1 (en) * | 2017-06-30 | 2019-01-03 | Cellectis | Cellular immunotherapy for repetitive administration |
| WO2019028051A1 (en) | 2017-07-31 | 2019-02-07 | Lentigen Technology, Inc. | COMPOSITIONS AND METHODS FOR TREATING CANCER BY ANTI-CD19 / CD20 IMMUNOTHERAPY |
| US12023353B2 (en) * | 2017-10-18 | 2024-07-02 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Methods and compounds for improved immune cell therapy |
| WO2019245817A1 (en) * | 2018-06-19 | 2019-12-26 | Armo Biosciences, Inc. | Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy |
| US12036242B2 (en) | 2018-07-05 | 2024-07-16 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | CAR T cells that target B-cell antigens |
| WO2020183158A1 (en) | 2019-03-11 | 2020-09-17 | Leucid Bio Ltd | MUC1 PARALLEL CAR (pCAR) THERAPEUTIC AGENTS |
| CN114127297A (zh) * | 2019-03-26 | 2022-03-01 | 加维什-加利里生物应用有限公司 | 遗传重编程的表达car的treg |
| EP3980035A4 (en) | 2019-06-07 | 2023-08-23 | The Board Of Trustees Of The Leland Stanford Junior University | FOXP-ENGINEERED CD4+ T-CELLS FOR USE IN TREG-BASED IMMUNOTHERAPY |
| WO2022005462A1 (en) | 2020-06-30 | 2022-01-06 | Tr1X, Inc. | Poly-donor cd4+ t cells expressing il-10 and uses thereof |
| WO2023025788A1 (en) * | 2021-08-24 | 2023-03-02 | Ecole Polytechnique Federale De Lausanne (Epfl) | Il-10 expressing cells for enhanced cancer immunotherapies |
-
2022
- 2022-12-27 WO PCT/US2022/082431 patent/WO2023129929A1/en not_active Ceased
- 2022-12-27 CA CA3244829A patent/CA3244829A1/en active Pending
- 2022-12-27 US US18/725,665 patent/US20250108113A1/en active Pending
- 2022-12-27 CN CN202280092915.2A patent/CN119136843A/zh active Pending
- 2022-12-27 TW TW111150212A patent/TW202334400A/zh unknown
- 2022-12-27 AU AU2022423984A patent/AU2022423984A1/en active Pending
- 2022-12-27 EP EP22854391.4A patent/EP4456927A1/en active Pending
- 2022-12-27 AR ARP220103606A patent/AR128124A1/es unknown
- 2022-12-27 IL IL313935A patent/IL313935A/en unknown
- 2022-12-27 JP JP2024539566A patent/JP2025503546A/ja active Pending
- 2022-12-27 KR KR1020247025594A patent/KR20250005566A/ko active Pending
-
2023
- 2023-03-30 AR ARP230100780A patent/AR128926A1/es unknown
-
2025
- 2025-02-26 US US19/064,325 patent/US12576150B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021221785B2 (en) | Engineered gamma delta T-cells | |
| JP2024138456A (ja) | 改変された制御性ｔ細胞 | |
| EP3368075B1 (en) | Chimeric antigen receptor molecules and uses thereof | |
| JP2025503546A5 (enExample) | ||
| EP2944652A1 (en) | Glypican-3-specific T-cell receptors and their uses for immunotherapy of hepatocellular carcinoma | |
| TWI899050B (zh) | 通用抗原呈現細胞及其用途 | |
| US20250002855A1 (en) | Methods for expanding t cells for the treatment of cancer and related malignancies | |
| JP2023538012A (ja) | 免疫細胞機能の改善 | |
| US20240216426A1 (en) | Recombinant antigen presenting cells | |
| CN116411025A (zh) | Sirt1-7蛋白在免疫治疗中的应用 | |
| CN118510901A (zh) | 嵌合衔接子多肽 | |
| CN117730094A (zh) | 用于肿瘤免疫学的组合物和方法 | |
| EP4173640A1 (en) | Method for stabilizing binding of antibody to nk cell and use thereof | |
| KR20220038776A (ko) | T 세포 수용체 및 이의 사용 방법 | |
| WO2024193714A1 (zh) | 细胞免疫疗法的组合物和方法 | |
| WO2023284875A1 (zh) | 嵌合抗原受体 | |
| WO2025247380A1 (en) | Nkg2d receptor and method of using thereof | |
| KR20220095228A (ko) | 암의 t 세포 치료를 위한 세포독성 효과기 기억 t 세포를 생산하는 방법 | |
| CN120005830A (zh) | 一种分泌cd47-pd-l1的基因修饰的免疫细胞的制备及应用 | |
| WO2024153124A1 (zh) | 经修饰的原代t细胞及其用途 | |
| WO2023123225A1 (zh) | Sirt1-7蛋白在免疫治疗中的应用 | |
| CN121800931A (zh) | 靶向cll1的增强型嵌合抗原受体及其应用 | |
| HK40085955A (en) | Method for stabilizing binding of antibody to nk cell and use thereof | |
| HK1260234B (en) | Chimeric antigen receptor molecules and uses thereof | |
| HK1260234A1 (en) | Chimeric antigen receptor molecules and uses thereof |